Journal: Frontiers in cell and developmental biology
Article Title: Monitoring the Sphingolipid de novo Synthesis by Stable-Isotope Labeling and Liquid Chromatography-Mass Spectrometry.
doi: 10.3389/fcell.2019.00210
Figure Lengend Snippet: FIGURE 7 | Impact of cofactor supplementation and presence of enzyme inhibitors on de novo formation of deuterated sphingolipid metabolites in the microsomal assay. Selected reaction monitoring (SRM) using a triple quadrupole mass spectrometer (TQ MS) was conducted to investigate the formation of 3KS-d5 (first column), d18:0 Sph-d5 (second column), Cer d18:0-d5/16:0-d3 (C16 dhCer-d8, third column) and Cer d18:1-d5/16:0-d3 (C16 Cer-d8, fourth column) under different assay conditions. The in vitro assay reaction mixture was prepared as described in section Materials and Methods with the following modifications: omission of NADPH (first row), “standard conditions” (with NADPH, second row), supplemented with NADPH and NADH (third to fifth row), addition of ceramide synthase (CerS) inhibitor fumonisin B1 (FB1, fourth row), and addition of serine palmitoyltransferase (SPT) inhibitor myriocin (Myr, fifth row). Signals that were not present in the corresponding negative controls were integrated and colored. d17:0 Sph (0.2 pmol injected on column) and Cer d18:1/17:0 (2 pmol injected on column), referred to as internal standards (IS) 1 and 2, respectively, were used to normalize areas under the curves (AUC). Corresponding relations are indicated as insets. Y axes are scaled differently, while x axes are maintained for each sphingolipid metabolite.
Article Snippet: Cer d18:0/16:0 (C16 dhCer), Cer d18:1/16:0 (C16 Cer), Cer d18:1/17:0 (C17 Cer), d18:0 Sph (dhSph) and d17:0 Sph were from Avanti Polar Lipids (Alabaster, United States).
Techniques: Targeted Proteomics, Mass Spectrometry, In Vitro, Injection